0000200406-26-000087
SEC filingJohnson & Johnson delivered 9.9% operational revenue growth to $24.1B, supported by strong commercial execution in MedTech and pharmaceutical demand. Profitability comparisons were impacted by a significant one-time benefit in the prior year period.
Johnson & Johnson reported Q1 FY2026 revenue of $24.1B, representing 9.9% operational growth over the prior year period. This performance was driven by strength across the portfolio, with Advanced Surgery benefiting from commercial execution in Biosurgery and new product launches in Energy. Pharmaceutical demand remained robust, particularly for SPRAVATO (esketamine), which saw continued increased physician and patient demand. Growth in the Surgical segment was supported by recent product innovations and strong commercial execution, though competitive pressures in the U.S. partially offset gains. Additionally, China volume-based procurement across all platforms and competitive pressures in Endocutters tempered overall growth.
Net income for Q1 FY2026 was $5.2B, or $2.14 per diluted share, compared to $11.0B, or $4.54 per diluted share, in the prior year period. The 52.4% decline in net income reflects the comparison against a prior year period that included substantial one-time benefits that did not recur in the current quarter. This dynamic underscores the importance of evaluating underlying operational performance rather than year-over-year GAAP comparisons for this period.
The Company continues to navigate a complex operating environment, balancing innovation-driven growth with competitive and regulatory pressures. Product launches in the MedTech segment and share gains in key pharmaceutical franchises position the Company for continued operational resilience, even as biosimilar competition impacts established products.